Eli Lilly's shareholders are in store for even more gains, according to a respected investment bank. The drugmaker is poised to profit from the rapid growth of the global obesity treatment market.
Eli Lilly and Intuitive Surgical are top players in their respective corners of the healthcare market. Both companies are highly innovative and boast attractive long-term growth opportunities.
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Eli Lilly (NYSE:LLY | LLY Price Prediction) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare.
Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43.